Expertise in
9
conditions

Dr. Albert S. Denittis

Radiation Oncology
Lankenau Medical Center
100 E Lancaster Ave, 
Wynnewood, PA 
Clinical Trials:Currently Recruiting for 4 Trials
Expertise in
9
conditions
Lankenau Medical Center
100 E Lancaster Ave, 
Wynnewood, PA 

Overview

Albert Denittis is a Radiation Oncologist practicing medicine in Wynnewood, Pennsylvania.

Dr. Denittis is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Cervical Cancer, Familial Prostate Cancer, and Neuroendocrine Carcinoma of the Cervix.

He is actively involved in clinical research, co-authoring 24 peer reviewed articles and participating in 78 clinical trials.

Specialties

Radiation Oncology

Licenses

Radiology in PA

Hospital Affiliations

Bryn Mawr Hospital
Riddle Memorial Hospital
Main Line Hospital Lankenau

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Lankenau Medical Center
100 E Lancaster Ave, Wynnewood, PA 19096
Other Locations
Office
1020 Boal Ave, Boalsburg, PA 16827

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

78 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Enrollment Status: Recruiting
Publish Date: September 04, 2026
Intervention Type: Drug, Procedure
Study Drug: Olaparib
Study Phase: Phase 2
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Enrollment Status: Recruiting
Publish Date: September 04, 2026
Intervention Type: Procedure, Other
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Recruiting
Publish Date: September 03, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Bevacizumab, Osimertinib
Study Phase: Phase 3
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
View 6 Less Clinical Trials

24 Total Publications

Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003.
Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 11, 2025
Similar Doctors
Expertise in
38
conditions
Dr. Keith A. Cengel
Radiation Oncology
Expertise in
38
conditions
Dr. Keith A. Cengel
Radiation Oncology
Referral may be required
Before you request

Penn Radiation Oncology Perelman - 2nd Floor

3400 Civic Center Boulevard, West Pavilion, 2nd Floor, 
Philadelphia, PA 
 (4.6 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Keith Cengel is a Radiation Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Cengel is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Mesothelioma, Lung Cancer, Metastatic Pleural Tumor, Small Cell Lung Cancer (SCLC), and Liver Embolization. Dr. Cengel is board certified in Radiation Oncology, 2008. Dr. Cengel is currently accepting new patients.

Expertise in
27
conditions
Dr. Jeffrey D. Bradley
Radiation Oncology
Expertise in
27
conditions
Dr. Jeffrey D. Bradley
Radiation Oncology
Referral may be required
Before you request

Penn Radiation Oncology Perelman-Concourse Level

3400 Civic Center Boulevard, Concourse Level, 
Philadelphia, PA 
 (4.6 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Bradley is a Radiation Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Bradley is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Epithelial Tumor. Dr. Bradley is board certified in Radiation Oncology, 1998. Dr. Bradley is currently accepting new patients.

Expertise in
34
conditions
Dr. Wenyin J. Shi
Radiation Oncology
Expertise in
34
conditions
Dr. Wenyin J. Shi
Radiation Oncology
Referral may be required

Radiation Oncology At Thomas Jefferson University Hospital

111 South 11th Street, Suite G-301, 
Philadelphia, PA 
 (6.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Wenyin Shi is a Radiation Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Shi is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Mycosis Fungoides, Glioblastoma, Brain Tumor, and Gamma Knife Radiosurgery. Dr. Shi is board certified in Radiation Oncology and Radiology. Dr. Shi is currently accepting new patients.

Frequently Asked Questions about Dr. Albert S. Denittis

How do I make an appointment with Dr. Albert S. Denittis?

You can book an appointment with Dr. Albert S. Denittis by calling their office at 484-476-2433. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Albert S. Denittis a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Albert S. Denittis is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Albert S. Denittis specialize in?

While Dr. Albert S. Denittis is a Radiation Oncology, they have specific expertise in Prostate Cancer, Cervical Cancer, and Familial Prostate Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Albert S. Denittis participate in research or clinical trials?

Yes. Dr. Albert S. Denittis has published 24 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Albert S. Denittis's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Albert S. Denittis accept my insurance?

Dr. Albert S. Denittis accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 484-476-2433 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Denittis's expertise for a condition
ConditionClose
    View All 36 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile